New shot method for rare lung disease shows promise in early trial

NCT ID NCT04722887

First seen Jan 04, 2026 · Last updated May 11, 2026 · Updated 23 times

Summary

This study tested a new way to give a protein replacement therapy (Alpha1-Proteinase Inhibitor) by injection under the skin instead of through a vein. It involved 17 adults with Alpha1-Antitrypsin Deficiency, a genetic condition that can damage the lungs. The main goal was to check if the treatment was safe and tolerable at two different doses given weekly for 8 weeks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALPHA1-ANTITRYPSIN DEFICIENCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Cleveland Clinic

    Cleveland, Ohio, 44195, United States

  • Medical University of South Carolina - Children's Hospital

    Charleston, South Carolina, 29425, United States

  • UCLA Medical Center

    Los Angeles, California, 90025, United States

  • University of Florida

    Gainesville, Florida, 32610, United States

  • University of Miami

    Miami, Florida, 33136, United States

Conditions

Explore the condition pages connected to this study.